– Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent genital herpes – – Statistically significant reductions in HSV-2 shedding rate, high viral load shedding rate and genital lesion rate observed in the cohort evaluating 350 mg weekly oral dose compared to placebo – – Interim data evaluating a monthly dosing regimen of ABI-5366 and weekly dosing for second HSV helicase-primase inhibitor candidate ABI-1179 expected to be shared later this fall – SOUTH SAN FRANCISCO, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that interim Phase 1b clinical data for its long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate ABI-5366 are featured in a late-breaking oral presentation during the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe, taking place October 9-11, 2025, in Athens, Greece.